Dextromethorphan-Bupropion (Auvelity) for Depression: Clinical Trial Data for the New Rapid-Acting Antidepressant
Major depressive disorder (MDD) is a significant global health concern, affecting over 280 million people worldwide. While numerous pharmacological options exist, challenges remain in achieving timely, robust, and sustained antidepressant response. Dextromethorphan-bupropion is a novel oral antidepressant recently approved by the FDA for MDD in adults that may address some of these unmet needs. Key …